Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Stopped early · Phase 2

Conditions studied: Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia

In brief

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Amifostine may decrease the side effects caused by chemotherapy and radiation therapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine in treating head and neck cancer. PURPOSE: This randomized phase II trial is studying amifostine to see how well it works compared with standard care in reducing side effects in patients undergoing chemotherapy and radiation therapy for stage III or stage IV head and neck cancer.

Key facts

Study ID

NCT00503776

Run by

Vanderbilt-Ingram Cancer Center

People needed

41

Starts

2006-01-01

Expected to finish

2008-08-01

Last updated by the study team

2017-06-20

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than 21
• Biopsy proven stage 3 or 4 squamous cell carcinoma of the larynx, pharynx, oral cavity or salivary glands
• No prior history of active cancer within three years other than non-melanoma skin cancer, early stage prostate or early stage cervical cancer
• controlled co-morbid disease
• ECOG PS of 0-3
• Plan for definitive or post-operative CCR within 4 weeks
• Written informed consent
• Working telephone
• May have received prior induction chemotherapy
• Agree to use only study supplied liquid nutrition supplements or dietary supplements, for per os or feeding tube intake

You may not qualify if…

• Diagnosed HIV or AIDS
• History of ETOH or drug abuse within 3 months
• Pregnant or lactating
• On steroid medication or prescribed NSAIDs
• Consuming specialty nutrition supplements containing additional amounts of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA)
• On orexigenic (appetite stimulant) medication.
• Uncontrolled comorbid disease defined as: a) severe cardiac disease Class III or greater; b) blood pressure > 160/95; c) uncontrolled pain
• Does not have working telephone.

Where it is running

• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.